Review




Structured Review

Simcyp pbpk
Pbpk, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/pbpk/pmc13136160-12-3-4
Average 86 stars, based on 1 article reviews
pbpk - by Bioz Stars, 2026-11
86/100 stars

Images

Related Articles

Biomarker Discovery:

Article Title: Pharmacometric modeling of opioid disposition in pregnancy: a systematic review of PopPK and PBPK approaches, model limitations, and future directions
Article Snippet: Buprenorphine , , PBPK (Simcyp v15.1) , AUC, Cavg, Cmax: within ±25% of observed means except Cavg in T3 (−26.3%) , Sublingual route implementation poorly documented → reproducibility concerns; underpredicted clearance in T2/T3 suggesting need to better characterize CYP3A4/UGT induction , , , , Pregnancy substantially reduces buprenorphine systemic exposure (∼50% in T3) due to increased hepatic clearance and volume of distribution, suggesting clinical need for increased dosing frequency. .. Buprenorphine , , PBPK (Simcyp v21.0) , Maternal AUC0-12h, CL, Cmax within 1.25-fold; fetal geometric mean predicted/observed cord blood = 1.15; 95.2% within 2-fold error , Empirical global scalar (0.26819) for Kp values lacking experimental validation; accurate fetal prediction required post hoc adjustment of maternal absorption; assumes pH-driven absorption reduction applies identically across formulations/doses , , , Fetal exposure increases throughout gestation; accurate prediction of fetal concentrations required post hoc optimization of maternal sublingual absorption to account for high inter-individual variability and pregnancy-induced reductions in salivary pH. .. Methadone , , PBPK (Simcyp v12.1); Maternal PBPK model with single placental-fetal compartment , Pred/Obs AUC Cmax within 0.8–1.25 in T2/T3 , CYP2B6 induction magnitude estimated from in vitro mRNA data (IVIVE), not calibrated against in vivo reference; validation using methadone potentially insensitive due to multiple clearance pathways (CYP2B6, 3A, 2C19, renal); unable to assess fetal disposition , , Model successfully predicted methadone PK in T2 (ratio 0.8–1.25); T3 predictions less robust, slightly underpredicting concentrations (AUC ratio 0.79).

Article Title: Pharmacometric modeling of opioid disposition in pregnancy: a systematic review of PopPK and PBPK approaches, model limitations, and future directions
Article Snippet: .. Codeine/Morphine , , PBPK (Simcyp v19.1); Full maternal and fetal PBPK models , Simulated/observed MFE ∼1.2 (codeine) and ∼1.15 (morphine) for AUC/Cmax fell within ≤2-fold acceptance criteria , Virtual populations only; no pregnant human genotype-stratified validation; Single dose simulation only(for lower back pain opioid may be taken multiple dose; fetal genotype mismatch ignored , , Maternal CYP2D6 phenotype significantly determined fetal exposure; ultra-rapid metabolizer (UM) cohort showed >1.65-fold increase in fetal morphine AUC compared to extensive metabolizers (EM). .. Sufentanil , , PopPK using NONMEM v7.4.0; 2-compartment model (maternal + umbilical compartments) , Model fit maternal venous and umbilical concentration vs. time data; VPCs reported , Concomitant ropivacaine may confound; very low intercompartmental clearance estimate (CL2 = 0.0134 L/h, representing 0.01% of maternal clearance) , , , , , Model predicts slow decline in umbilical cord concentration after epidural infusion discontinuation, suggesting sufentanil sequestered in placenta due to high lipophilicity and released slowly back into fetal circulation.

Formulation:

Article Title: Physiologically‐based pharmacokinetic modelling of a CYP2C19 substrate, BMS‐823778, utilizing pharmacogenetic data
Article Snippet: .. The blood/plasma partition ratio was determined to be 0.8. table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Parameters Values Parameters Values MW (g mol –1 ) 328 CYP3A4 K m = 62.77 μmol l –1 Fraction of unbound (f u ) 0.15 V max = 0.35 (pmol min 1 pmol protein –1 ) Blood/plasma 0.8 REF = 1 pKa 3.5 CYP2C19 K m = 33.85 μmol l –1 LogPo:w 2.76 V max = 1.48 (pmol/min/pmol protein) Absorption ADAM model REF = 8 P eff,man (10 –4 cm s –1 ) 7.01 UGT1A4 CL int = 0.012 (μl min –1 mg –1 protein) F uGut 1 CL R (L/h) 0.007 Formulation solution f a 0.99 predicted in Simcyp Distribution Full PBPK f g 0.97–0.99 predicted in Simcyp K p scalar 1 f h 0.92–0.97 predicted in Simcyp V ss (l kg –1 ) 1.88 F% 0.90–0.96 predicted in Simcyp Biliary clearance (l h –1 ) 0.6 (100% re‐absorb) Open in a separate window Tissue:plasma partition coefficients were taken directly from the rat tissue distribution study; Kp values are listed in Table S1 ( Supporting Information ). ..

Concentration Assay:

Article Title: Drug-Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model.
Article Snippet: .. Simulations Using a PBPK Model A minimal PBPK model (Simcyp, Version 19) developed previously was verified (see Supplemental Information for verification details) by comparing simulated concentration–time profiles and observed concentrations for mavacamten and for EE with and without concomitant administration of mavacamten. ..

other:

Article Title: Toward improved predictions of pharmacokinetics of transported drugs in hepatic impairment: Insights from the extended clearance model
Article Snippet: Indeed, whereas the AUCR HI of OATP/BET substrates pitavastatin, rosuvastatin, valsartan, and gadoxetic acid was relatively well‐predicted by PBPK M&S (Simcyp version 21; Figure ), there was a trend towards underprediction for the two dual OATP/CYP3A4 substrates (Figure ).



Similar Products

90
Simcyp simcyp® v21
Simcyp® V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v19/pm39934586-93-16-16
Average 90 stars, based on 1 article reviews
simcyp® v21 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Certara L.P simcyp v21
Simcyp V21, supplied by Certara L.P, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v21/med_rxiv__2024__12__17__24319139-27-5-7
Average 90 stars, based on 1 article reviews
simcyp v21 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Simcyp simcyp v21
Simcyp V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v19/pm39656410-3-24-25
Average 90 stars, based on 1 article reviews
simcyp v21 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Simcyp dynamic simulations simcyp v21
Dynamic Simulations Simcyp V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v19/pmc11762507-60-25-26
Average 90 stars, based on 1 article reviews
dynamic simulations simcyp v21 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Certara L.P simcyp pbpk simulator v21
Key <t>PBPK</t> modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.
Simcyp Pbpk Simulator V21, supplied by Certara L.P, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+simulator+v23/pmc11773107-133-6-10
Average 90 stars, based on 1 article reviews
simcyp pbpk simulator v21 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Simcyp simcyp simulator v21
Key <t>PBPK</t> modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.
Simcyp Simulator V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v19/pm39218776-573-17-17
Average 90 stars, based on 1 article reviews
simcyp simulator v21 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Simcyp pbpk model using simcyp® v21 simulator
Key <t>PBPK</t> modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.
Pbpk Model Using Simcyp® V21 Simulator, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/13+compartment+full+pbpk+model+simcyp++population+based+simulator+version+12+1/pm39218776-551-31-31
Average 90 stars, based on 1 article reviews
pbpk model using simcyp® v21 simulator - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Certara L.P simcyp™ pbpk simulator v21 release 1
Key <t>PBPK</t> modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.
Simcyp™ Pbpk Simulator V21 Release 1, supplied by Certara L.P, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+simulator+v23/pm38923321-40-3-8
Average 90 stars, based on 1 article reviews
simcyp™ pbpk simulator v21 release 1 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Simcyp simcyp v21 simulator
Key <t>PBPK</t> modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.
Simcyp V21 Simulator, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/simcyp+v19/pmc11533107__PSP4___13___1528___s001-21-19-19
Average 90 stars, based on 1 article reviews
simcyp v21 simulator - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Simcyp caffeine, s-warfarin, omeprazole, midazolam, simvastatin and cyclosporin compound files from simcyp v21
Key <t>PBPK</t> modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.
Caffeine, S Warfarin, Omeprazole, Midazolam, Simvastatin And Cyclosporin Compound Files From Simcyp V21, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/simcyp+v21/caffeine++s+warfarin++omeprazole++midazolam++simvastatin+and+cyclosporin+compound+files+from+simcyp+v21/pmc11247108-78-12-21
Average 90 stars, based on 1 article reviews
caffeine, s-warfarin, omeprazole, midazolam, simvastatin and cyclosporin compound files from simcyp v21 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Key PBPK modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.

Journal: British Journal of Clinical Pharmacology

Article Title: Physiologically based pharmacokinetic modelling to predict potential drug–drug interactions of dersimelagon (MT‐7117)

doi: 10.1111/bcp.16271

Figure Lengend Snippet: Key PBPK modelling steps and components of each clinical study used in model development, refinement, verification and application. BCRP, breast cancer resistance protein; DDI, drug–drug interaction; fu inc , fraction of unbound dersimelagon in in vitro system; K m , Michaelis constant; MAD, multiple ascending dose; OATP, organic anion transporting polypeptide; PBPK, physiologically based pharmacokinetic; PK, pharmacokinetic; QD, once daily; V max , maximum velocity of reaction; V ss , volume of distribution at steady state.

Article Snippet: All simulations were conducted using the Simcyp PBPK Simulator v21 (Certara), which integrates demographic, physiological, genomic and in vitro biochemical data to allow prediction of PK in virtual healthy populations.

Techniques: In Vitro

Input parameters of the  physiologically based pharmacokinetic  model for dersimelagon.

Journal: British Journal of Clinical Pharmacology

Article Title: Physiologically based pharmacokinetic modelling to predict potential drug–drug interactions of dersimelagon (MT‐7117)

doi: 10.1111/bcp.16271

Figure Lengend Snippet: Input parameters of the physiologically based pharmacokinetic model for dersimelagon.

Article Snippet: All simulations were conducted using the Simcyp PBPK Simulator v21 (Certara), which integrates demographic, physiological, genomic and in vitro biochemical data to allow prediction of PK in virtual healthy populations.

Techniques: Binding Assay, Software, Permeability, In Vitro, Inhibition